Leadership
Deep, specialized expertise in dermatology, inflammation and immunology
Leadership
President and CEO
Chief Medical Officer
Chief Technical Officer
Chief Financial Officer
Chief Commercial Officer
General Counsel
Senior Vice President, Manufacturing
Vice President, Clinical Development
Vice President, Finance
Vice President, Clinical Operations
Vice President, Regulatory Affairs
Vice President, Biometrics
Vice President, Medical Affairs
Board of Directors
Chairman of the Board
Co-Founder
President and CEO
Scientific Advisors
Strategic Collaborations
Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast.
In December 2019, Arcutis exercised its option under a 2018 License Agreement with Jiangsu Hengrui Medicine Co., Ltd. of China (Hengrui) for an exclusive license to the active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), for all topical dermatological uses in the United States, Canada, Europe and Japan. Arcutis plans to develop ARQ-252 for hand eczema and other inflammatory dermatoses.